文献速递肝病

乳酸脱氢酶B乙酰化通过损害乳酸清除驱动NAFLD进展

Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
PubMed 文献 · J Hepatol · 2020-11-26

该研究比较健康人、单纯性脂肪变性和NASH患者肝样本的乙酰化组,发现LDHB K82位点经PCAF介导乙酰化后活性下降、肝脏乳酸清除受损,乳酸蓄积通过激活组蛋白高乙酰化加剧脂质沉积和炎症;PCAF抑制剂embelin或LDHB乙酰化缺陷突变可改善小鼠NASH。

要点

  • NAFLD进展中LDHB K82乙酰化升高与肝脏乳酸蓄积相关。
  • PCAF介导的LDHB乙酰化降低酶活性并损害肝脏乳酸清除。
  • 抑制PCAF或阻断LDHB乙酰化可改善HFD小鼠NASH。

核心结论

  • PCAF依赖的LDHB乙酰化通过损害乳酸清除在肝脏脂质蓄积和炎症反应中起关键作用,可能是NASH治疗的潜在靶点。

研究设计与样本

  • 研究比较健康个体、单纯性脂肪变性患者和NASH患者肝样本的乙酰化组,并在多种细胞系中检测乙酰化靶点与乙酰转移酶相互作用。
  • 研究向高脂饮食喂养小鼠注射乙酰转移酶抑制剂,以在体内确定乳酸对NAFLD进展的作用。

主要发现

  • 在人和小鼠的NAFL与NASH肝脏中,LDHB超乙酰化与乳酸蓄积相关。
  • PCAF介导的LDHB K82乙酰化显著降低LDHB活性并损害肝脏乳酸清除,导致乳酸蓄积。
  • 乙酰化LDHB诱导的乳酸蓄积通过激活组蛋白高乙酰化加剧HFD诱导NASH的脂质沉积和炎症反应。
  • 给予PCAF抑制剂embelin或生成LDHB乙酰化缺陷突变体可改善NASH。

临床怎么用

  • PCAF-LDHB乙酰化轴及肝脏乳酸清除可作为NASH潜在干预靶点,embelin和LDHB乙酰化缺陷突变在动物模型中显示改善NASH的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Lactate has recently been reported to accumulate in the livers of patients progressing from simple steatosis to non-alcoholic steatohepatitis (NASH). However, the underlying mechanism(s) of lactate accumulation and the role of lactate in the progression of non-alcoholic fatty liver disease (NAFLD) are essentially unknown. METHODS: We compared the acetylome in liver samples taken from healthy individuals, patients with simple steatosis and patients with NASH to identify potential targets of acetylation with a role in lactate metabolism. Interactions between the acetylated target and acetyltransferases were measured in multiple cell lines. An acetyltransferase inhibitor was injected into high-fat diet (HFD)-fed mice to determine the role of lactate on NAFLD progression in vivo. RESULTS: Hyperacetylation of lactate dehydrogenase B (LDHB) was found to be associated with lactate accumulation in NAFL and NASH livers in humans and mice. P300/CBP-associated factor (PCAF)-mediated acetylation of LDHB K82 was found to significantly decrease LDHB activity and impair hepatic lactate clearance, resulting in lactate accumulation. Acetylated LDHB induced lactate accumulation which exacerbated lipid deposition and inflammatory responses by activating histone hyperacetylation in HFD-induced NASH. The administration of embelin, a PCAF inhibitor, and the generation of an acetylation-deficient mutant of LDHB ameliorated NASH. CONCLUSION: PCAF-dependent LDHB acetylation plays a key role in hepatic lipid accumulation and inflammatory responses by impairing lactate clearance; this process might be a potential therapeutic target for the treatment of NASH. LAY SUMMARY: Lactate is known to accumulate in the livers of patients during the progression of non-alcoholic fatty liver disease (NAFLD); however, the underlying mechanism(s) of this accumulation and its importance in disease progression are unknown. Herein, we show that the acetylation of an enzyme involved in lactate metabolism leads to impaired lactate clearance and exacerbates NAFLD progression.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang T, Chen K, Yao W, et al. Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance. J Hepatol. 2020. PMID: 33248168. doi:10.1016/j.jhep.2020.11.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。